Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[21] A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard- Risk Patients
Gay, Francesca Maria
Scalabrini, Delia Rota
Belotti, Angelo
Galli, Monica
Zamagni, Elena
Offidani, Massimo
Oliva, Stefania
Montefusco, Vittorio
Zambello, Renato
Ledda, Antonio
Grasso, Mariella
Aquino, Sara
Esma, Fabrizio
Tosi, Patrizia
Pisani, Francesco
Annibali, Ombretta
Liberati, Anna Marina
Baraldi, Anna
Galieni, Piero
Specchia, Giorgina
Pescosta, Norbert
Mancuso, Katia
Paris, Laura
Ribolla, Rossella
Coha, Valentina
Palumbo, Antonio
Musto, Pellegrino
Cavo, Michele
Boccadoro, Mario
BLOOD, 2017, 130
[22] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Zimmerman, Todd
Raje, Noopur S.
Vij, Ravi
Reece, Donna
Berdeja, Jesus G.
Stephens, Leonor A.
McDonnell, Kathryn
Rosenbaum, Cara A.
Jasielec, Jagoda
Richardson, Paul G.
Gurbuxani, Sandeep
Nam, Jennifer
Severson, Erica
Wolfe, Brittany D.
Rosebeck, Shaun
Stefka, Andrew
Dytfeld, Dominik
Griffith, Kent
Jakubowiak, Andrzej
BLOOD, 2016, 128 (22)
[23] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Zimmerman, T. M.
Griffith, K.
Jasielec, J. K.
Rosenbaum, C. A.
McDonnell, K.
Marin, J.
Bakker, J.
Berdeja, J. G.
Vij, R.
Jakubowiak, A. J.
HAEMATOLOGICA, 2014, 99 : 103 - 103
[24] Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies
Landgren, Ola
Attal, Michel
Kazandjian, Dickran
Roussel, Murielle
Jasielec, Jagoda K.
Dytfeld, Dominik
Anderson, Aparna
Kervin, Tara
Iskander, Karim
Mezzi, Khalid
Welliver, Tim
Yusuf, Akeem
Jakubowiak, Andrzej
BLOOD, 2019, 134
[25] VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Piedra, Katrina M.
Hassoun, Hani
Buie, Larry W.
Devlin, Sean M.
Flynn, Jessica
Hultcrantz, Malin
Lesokhin, Alexander M.
Lu, Sydney X.
Mailankody, Sham
Shah, Urvi A.
Smith, Eric L.
Landgren, Ola
Korde, Neha
Peterson, Tim J.
BLOOD, 2019, 134
[26] A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group
Gregersen, Henrik
Peceliunas, Valdas
Remes, Kari
Schjesvold, Fredrik H.
Abildgaard, Niels
Nahi, Hareth
Andersen, Niels Frost
Vangsted, Annette Juul
Klausen, Tobias Wirenfeldt
Helleberg, Carsten
Carlson, Kristina
Frolund, Ulf Christian
Axelsson, Per
Stromberg, Olga
Blimark, Cecilie Hveding
Linder, Olle
Tsykunova, Galina
Waage, Anders
Hansson, Markus
Gulbrandsen, Nina
BLOOD, 2019, 134
[27] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Wang, Yuqi
Huan, Chen
Hanzhen, Zhang
Zhang, Shanshan
Yuan, Youhai
Feng, Ru
Wei, Yongqiang
Wei, Xiaolei
BLOOD, 2024, 144 : 7031 - 7031
[28] Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma
Gavriatopoulou, Maria
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Eleutherakis-Papaiakovou, Evangelos
Papatheodorou, Athanasios
Kanellias, Nikolaos
Migkou, Magdalini
Fotiou, Despina
Dialoupi, Ioanna
Roussou, Maria
Kokkali, Nikoletta-Aikaterini
Kastritis, Eftathios
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[29] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Maria Gavriatopoulou
Evangelos Terpos
Ioannis Ntanasis-Stathopoulos
Panagiotis Malandrakis
Evangelos Eleutherakis-Papaiakovou
Athanasios Papatheodorou
Nikolaos Kanellias
Magdalini Migkou
Despina Fotiou
Ioanna Dialoupi
Maria Roussou
Nikoletta-Aikaterini Kokkali
Efstathios Kastritis
Meletios A. Dimopoulos
Blood Cancer Journal, 10
[30] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Gavriatopoulou, Maria
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Eleutherakis-Papaiakovou, Evangelos
Papatheodorou, Athanasios
Kanellias, Nikolaos
Migkou, Magdalini
Fotiou, Despina
Dialoupi, Ioanna
Roussou, Maria
Kokkali, Nikoletta-Aikaterini
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD CANCER JOURNAL, 2020, 10 (03)

← 1 2 3 4 5 →